MacroGenics | MGNX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
Biogen USD 1.82B 169.5M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Genmab DKK 977M 13M 2025-12
Geron USD 46.71M 525K 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
J&J USD 17.24B 642M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck USD 10.85B 2.57B 2025-12
Pfizer USD 12.28B 8.74B 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Xencor USD 21M 22.61M 2025-09